Copy of Dr. Wong Discusses the FDA Approval of Elotuzumab Triplet in Myeloma

Dr. Wong Discusses the FDA Approval of Elotuzumab Triplet in MyelomaПодробнее

Dr. Anderson on Recent FDA Approvals in Multiple MyelomaПодробнее

Elotuzumab with Car/Pom/Dex for high-risk R/R myelomaПодробнее

Elotuzumab in Relapsed/Refractory Multiple MyelomaПодробнее

Dr. Martin on FDA Approval of Denosumab in Multiple MyelomaПодробнее

FDA Labels of New Multiple Myeloma AgentsПодробнее

What is the status of Empliciti® (elotuzumab), the new immunotherapy?Подробнее

Efficacy and Safety of Elotuzumab and DaratumumabПодробнее

A New Multiple Myeloma TreatmentПодробнее

Can We Detect Myeloma Even Sooner?Подробнее

All About Empliciti (Elotuzumab) #myelomaПодробнее

Dr. Wong on an Investigational Antibody-Drug Conjugate in Multiple MyelomaПодробнее

Copy of Dr. Vij Discusses the Potential of Quadruplets in MyelomaПодробнее

The recent FDA approval of cilta-cel and its impact on myeloma patients in the UKПодробнее

FDA Guidelines in Male Breast Cancer, Encouraging Data in Breast Cancer and Myeloma, and MoreПодробнее

How important is the FDA approval of once-weekly dosage of Kyprolis for multiple myeloma patients?Подробнее

2019 Multiple Myeloma Symposium | Novel and Next Generation TherapyПодробнее

A Big Month for Multiple MyelomaПодробнее

Empliciti (Elotuzumab) A New Immunotherapy Cancer Treatment for Multiple MyelomaПодробнее